The DOI matches its Crossref record; 215 of the 290 references it cites were found in a registry or an index, and 72 are not checked yet; none of the 223 sources its claims cite is checked for support yet.
Epigenetics and cancer
Open accessAbstract
Epigenetic mechanisms act to change the accessibility of chromatin to transcriptional regulation locally and globally via modifications of the DNA and by modification or rearrangement of nucleosomes. Epigenetic gene regulation collaborates with genetic alterations in cancer development. This is evident from every aspect of tumor biology including cell growth and differentiation, cell cycle control, DNA repair, angiogenesis, migration, and evasion of host immunosurveillance. In contrast to genetic cancer causes, the possibility of reversing epigenetic codes may provide new targets for therapeutic intervention.
Checked 2026-10-06 · 72 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 223 cited sources checked · 0 supported · 0 flagged
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Epigenetic gene regulation collaborates with genetic alterations in cancer development.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This is evident from every aspect of tumor biology including cell growth and differentiation, cell cycle control, DNA repair, angiogenesis, migration, and evasion of host immunosurveillance.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, other genes, such as cell cycle checkpoint genes and genes directly affected by exogenous stimuli such as growth factors or cell-cell contact, likely reside in a balanced state sensitive to dynamic adjustments in histone modifications, thereby allowing for rapid responses to specific stimuli.”
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Ser 10 phosphorylation also facilitates acetylation of Lys 9, thereby preventing the setting of repressive Lys 9 methylation marks (Rea et al. 2000).”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
What the sources say
- Not checked yetcites Rea et al. 2000
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Not surprisingly therefore, epigenetic gene regulation is characterized overall by a high degree of integrity and stability.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Trimethylation of Lys 4 on histone H3 correlates with transcriptional activity (Santos-Rosa et al. 2002),”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Santos-Rosa et al. 2002
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“EZH2 is overexpressed in many cancers (Varambally et al. 2002;Bracken et al. 2003;Kleer et al. 2003;Raaphorst et al. 2003)”
§ REVIEW Epigenetics and cancer > Setting Polycomb imprints
What the sources say
- Not checked yetcites Varambally et al. 2002
- Not checked yetcites Bracken et al. 2003
- Not checked yetcites Kleer et al. 2003
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“the expression level of EZH2 correlates with a poorer prognosis in both prostate (Varambally et al. 2002) and breast cancer (Kleer et al. 2003).”
§ REVIEW Epigenetics and cancer > Setting Polycomb imprints
What the sources say
- Not checked yetcites Varambally et al. 2002
- Not checked yetcites Kleer et al. 2003
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“and the other four human MLL homologs all reside in cancer-related loci.”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“A second group of proteins, containing bromodomain and chromodomain modules, use the epigenetic marks on the histone tails as recognition landmarks to bind the chromatin and initiate downstream biological processes such as chromatin compaction, transcriptional regulation, or DNA repair (Fig. 2).”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 70
- Probably not a substantial claim. 19
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast to genetic cancer causes, the possibility of reversing epigenetic codes may provide new targets for therapeutic intervention.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Epigenetic changes that contribute to cancer can be reversed pharmacologically to produce therapeutic benefit.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Aside from the core histones, a variety of variant histone proteins exist and can be inserted into the nucleosome, possibly serving as landmarks for specific cellular functions (discussed following).”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Surprisingly, although PRC2 complex members are directly controlled by the RB tumor-suppressor pathway, their expression levels do not appear to fluctuate in a cell cycle-dependent manner (Weinmann et al. 2001;Bracken et al. 2003).”
§ REVIEW Epigenetics and cancer > Setting Polycomb imprints
What the sources say
- Not checked yetcites Weinmann et al. 2001
- Not checked yetcites Bracken et al. 2003
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“This is exemplified in gene activation where phosphorylation of histone H3 Ser 10 facilitates acetylation of Lys 14 and methylation of Lys 4, resulting in an open chromatin conformation (Cheung et al. 2000;Lo et al. 2000).”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
What the sources say
- Not checked yetcites Cheung et al. 2000
- Not checked yetcites Lo et al. 2000
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The pattern of histone modifications signifies the status of the chromatin locally and has been coined the histone code (Strahl and Allis 2000).”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
What the sources say
- Not checked yetcites Strahl and Allis 2000
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Epigenetic programming is crucial in mammalian development, and stable inheritance of epigenetic settings is essential for the maintenance of tissue-and cell-typespecific functions (Li 2002).”
What the sources say
- Not checked yetcites Li 2002
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These functions point to long-range mechanisms of transcriptional repression and suggest that PRC2 activity may have global consequences to the cell, perhaps via more generally skewing the balance between specific histone methylation imprints.”
§ REVIEW Epigenetics and cancer > Setting Polycomb imprints
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“histone methylations can serve as anchorage points for both activator and repressor complexes and are thereby involved in conferring an epigenetic inheritance to the cell, carrying information related to differentiation commitment and function.”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The nucleosome is made up of approximately two turns of DNA wrapped around a histone octamer built from two subunits of each histone, H2A, H2B, H3, and H4, respectively, In between core nucleosomes, the linker histone H1 attaches and facilitates further compaction (for a recent review, see Khorasanizadeh 2004).”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
What the sources say
- Not checked yetcites Khorasanizadeh 2004
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Polycomb-group (PcG) proteins form transcriptional repressor modules that functionally can be divided into at least two distinct complexes: the initiation complex, Polycomb repression complex 2 (PRC2), the core of which in humans consists of EZH2, EED, and SUZ12; and the maintenance complex, PRC1, with the core proteins RNF2, HPC, EDR, and BMI1.”
§ REVIEW Epigenetics and cancer > Setting Polycomb imprints
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Al-though histone acetylation in general correlates with transcriptional activity,”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“however, experimental overexpression of EZH2 results in target gene suppression only (Varambally et al. 2002), and hence does not sustain a notion of dominant negative effects.”
§ REVIEW Epigenetics and cancer > Setting Polycomb imprints
What the sources say
- Not checked yetcites Varambally et al. 2002
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“and the observed overexpression of EZH2 in cancers is likely causally related to tumorigenesis and not a mere consequence of deregulated RB-E2F functioning, as the EZH2 locus is amplified in several cancers (Bracken et al. 2003).”
§ REVIEW Epigenetics and cancer > Setting Polycomb imprints
What the sources say
- Not checked yetcites Bracken et al. 2003
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although most histone modifications are reversible, no histone demethylase has been identified as yet, suggesting histone methylation to be involved in processes of long-term regulation.”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The N-terminal tails of the histone proteins are protruding out from the nucleosomal core particles, and these tails serve as regulatory registers onto which epigenetic signals can be written.”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Recent data have demonstrated that the SET domain present in EZH2 is responsible for methylation of Lys 9 and, more prominently, Lys 27 of histone H3 (Cao et al. 2002;Czermin et al. 2002;Kuzmichev et al. 2002;Muller et al. 2002) and Lys 26 on histone H1 (Kuzmichev et al. 2004).”
§ REVIEW Epigenetics and cancer > Setting Polycomb imprints
What the sources say
- Not checked yetcites Cao et al. 2002
- Not checked yetcites Czermin et al. 2002
- Not checked yetcites Kuzmichev et al. 2004
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Also DNA methylation affects histone modifications and vice versa, to make up a highly intricate epigenetic control mechanism, the impact of which we have only just begun to comprehend.”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Members of both PcG and TrxG protein complexes harbor SET domains.”
§ REVIEW Epigenetics and cancer > Setting Polycomb imprints
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The PRC2 complex is also required for X-chromosome inactivation (Plath et al. 2003;Silva et al. 2003) and for correct imprinting of autosomal loci (Wang et al. 2001b).”
§ REVIEW Epigenetics and cancer > Setting Polycomb imprints
What the sources say
- Not checked yetcites Plath et al. 2003
- Not checked yetcites Silva et al. 2003
- Not checked yetcites Wang et al. 2001b
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Covalent modification of histones includes acetylation of lysines, methylation of lysines and arginines, phosphorylations of serines and threonines, ADP-ribosylation of glutamic acids, and ubiquitination and sumolyation of lysine residues (Fig. 1).”
§ REVIEW Epigenetics and cancer > Epigenetic gene regulation
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Histone proteins can be mono-, di-, or trimethylated at the amino group of lysine residues and either mono-or dimethylated at arginine residues.”
§ REVIEW Epigenetics and cancer > Histone modification: setting the mark
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This, however, remains to be confirmed in mouse models.”
§ REVIEW Epigenetics and cancer > Setting Polycomb imprints
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“SMYD3 was found to interact with the RNA polymerase II complex and activate target genes via methylation of histone H3 Lys 4.”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Evi1 was characterized in the mouse as a cancer-related retroviral integration site in myeloid leukemia (Morishita et al. 1988), and EVI1 was subsequently identified as a translocation breakpoint in hu-mans (Morishita et al. 1992).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Morishita et al. 1988
- Not checked yetcites Morishita et al. 1992
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Mll heterozygous mice do not appear tumor prone, making haploinsufficiency a less likely cause of leukemogenesis (Corral et al. 1996).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Corral et al. 1996
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Whereas Suv39h deficiency in the mouse predominantly was found to affect heterochromatin stability, the Suv39h methyltransferases associate with numerous proteins involved in cell cycle regulation including pRB (Nielsen et al. 2001;Vandel et al. 2001), PcG-proteins (Sewalt et al. 2002), and SMADs (Frontelo et al. 2004).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Nielsen et al. 2001
- Not checked yetcites Vandel et al. 2001
- Not checked yetcites Sewalt et al. 2002
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“SUV39H1 is the mammalian homolog of the Drosophila position effect variegation modifier Su(var)3-9 and was the first SET domain protein to be recognized as a histone methyl transferase (Rea et al. 2000).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Rea et al. 2000
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The Ash1-specific methylation imprint was found to displace HP1 and PcG proteins, which are normally bound to repressed genes, and instead facilitates the binding of the Brahma chromatin remodeling complex (Beisel et al. 2002).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Beisel et al. 2002
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This suggests a functional redundancy between different epigenetic gene repression mechanisms, which may serve to explain why loss of Suv39h-mediated repression does not have an even stronger phenotype.”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Intriguingly, all fusion proteins retain the N-terminal part of MLL1, whereas the C-terminal part encoding the SET domain is lost.”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In accordance with a tumor-suppressive function of RIZ1, ectopic expression in cancer cell lines results in cell cycle arrest and/or apoptosis (He et al. 1998;Jiang et al. 1999).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites He et al. 1998
- Not checked yetcites Jiang et al. 1999
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“RIZ1, originally isolated from its interaction with the RB tumor suppressor protein (Buyse et al. 1995), was the first SET domain protein demonstrated to be a tumor suppressor (Steele-Perkins et al. 2001).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Buyse et al. 1995
- Not checked yetcites Steele-Perkins et al. 2001
Strength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Mice deficient for the two Suv39 homologs display chromosomal instability and are prone to develop B-cell lymphomas resembling human non-Hodgkin lymphomas, albeit with long latency (Peters et al. 2001).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Peters et al. 2001
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In embryonic stem (ES) cells lacking both Suv39 homologs the pericentromeric heterochromatin is devoid of the characteristic trimethylation of histone H3, Lys 9. Instead, an alternative methylation imprint consisting of monomethylated Lys 9 and trimethylated Lys 27 has accumulated (Peters et al. 2003).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Peters et al. 2003
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The 5Ј MDS part of MDS-EVI1 contains a SET domain, and both retroviral integrations in the mouse and translocations in humans result in the selective overexpression of the EVI1 variant lacking a SET domain.”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“SMYD3 was recently identified as a SET and MYND domain-containing protein overexpressed in colorectal carcinomas and hepatocellular carcinomas (Hamamoto et al. 2004).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Hamamoto et al. 2004
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Interestingly, only RIZ1 harbors a SET domain and appears to be the main target of inactivation in tumors (Huang 2002),”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Huang 2002
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Whereas the oncogenic capacity of SMYD3 is yet to be confirmed in an in vivo model, overexpression of SMYD3 results in colony formation of NIH 3T3 cells.”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The reduced histone H3 methylation resulting from loss of Suv39h caused a decrease in HP1 association to the telomeres and abnormal telomere elongation (Garcia- Cao et al. 2004).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Garcia-Cao et al. 2004
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“More than 40 specific translocations involving MLL1 have been described in human cancers to date (Ayton and Cleary 2001).”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
What the sources say
- Not checked yetcites Ayton and Cleary 2001
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Interestingly, the MYND domain appears to confer sequence-specific binding to target genes.”
§ REVIEW Epigenetics and cancer > Setting Trithorax imprints
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Likewise, RNAi-mediated knockdown of HDAC2 in colonic cancer cells resulted in cell death, indicating a role for HDAC2 in protecting cancer cells against apoptosis (Zhu et al. 2004a).”
§ REVIEW Epigenetics and cancer > Histone acetylation
What the sources say
- Not checked yetcites Zhu et al. 2004a
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Aside from histones, many transcriptional regulators, chromatin modifiers, and intracellular signal transducers are posttranslationally modified by acetylation.”
§ REVIEW Epigenetics and cancer > Histone acetylation
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Dnmt1 was shown to be necessary and sufficient for Fos-induced transformation of mouse fibroblast cells (Bakin and Curran 1999),”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Bakin and Curran 1999
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“On the other hand is the reliance of important tumorsuppressor mechanisms on HDAC function, as exemplified by the dependency of RB on HDAC1 for transcriptional repression of E2F target genes (Luo et al. 1998;Magnaghi-Jaulin et al. 1998;Robertson et al. 2000).”
§ REVIEW Epigenetics and cancer > Histone acetylation
What the sources say
- Not checked yetcites Luo et al. 1998
- Not checked yetcites Magnaghi-Jaulin et al. 1998
- Not checked yetcites Robertson et al. 2000
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“DNA methylation is tightly connected to cancer development and can act as a double-edged sword.”
§ REVIEW Epigenetics and cancer > DNA methylation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“DNMT1 associates with the DNA replication fork and functions as a hemi-methylase responsible for maintaining correct methylation patterns on DNA replication.”
§ REVIEW Epigenetics and cancer > DNA methylation
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“All three methyltransferase enzymes have been found to be overexpressed in human tumors, although to moderate levels only (De Marzo et al. 1999;Robertson et al. 1999;Girault et al. 2003;Nagai et al. 2003).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites De Marzo et al. 1999
- Not checked yetcites Robertson et al. 1999
- Not checked yetcites Girault et al. 2003
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“CpG islands are most often associated with promoter regions and an estimated 60% of human genes contain a CpG island (Antequera and Bird 1993).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Antequera and Bird 1993
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Germ-line mutations in DNMT3B underlies ICF syndrome, a rare disorder characterized by immunodeficiency, centromeric instability, and facial abnormalities (Hansen et al. 1999;Xu et al. 1999).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Hansen et al. 1999
- Not checked yetcites Xu et al. 1999
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Hdac1-deficient mice are not viable and ES cells with homozygous Hdac1 deletion display proliferation defects correlating with increased levels of the cyclin-dependent kinase inhibitors p21 and p27 (Lagger et al. 2002), demonstrating the involvement of HDAC1 in cell cycle regulation.”
§ REVIEW Epigenetics and cancer > Histone acetylation
What the sources say
- Not checked yetcites Lagger et al. 2002
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Germ-line mutations in CBP causes the developmental disorder Rubenstein-Taybi syndrome, and these patients suffer an increased cancer risk (Petrij et al. 1995;Murata et al. 2001).”
§ REVIEW Epigenetics and cancer > Histone acetylation
What the sources say
- Not checked yetcites Petrij et al. 1995
- Not checked yetcites Murata et al. 2001
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although no arginine-specific methyltransferases have been implicated in cancer development yet, several of these enzymes are involved in gene regulatory complexes important for cell cycle regulation.”
§ REVIEW Epigenetics and cancer > Arginine methyltransferases
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“PRMT5 was furthermore found to associate with and negatively regulate the cyclin E promoter (Fabbrizio et al. 2002).”
§ REVIEW Epigenetics and cancer > Arginine methyltransferases
What the sources say
- Not checked yetcites Fabbrizio et al. 2002
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Patterns of DNA methylation are laid out during early embryogenesis via the interplay of at least three active DNA methyltransferases, DNMT1, DNMT3A, and DNMT3B, and targeted deletions of these genes in the mouse have demonstrated that the enzymes are essential for normal development (Li et al. 1992;Okano et al. 1999).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Li et al. 1992
- Not checked yetcites Okano et al. 1999
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Methylation at the C-5 position of cytosine residues present in CpG dinucleotides by DNMTs has evolved relatively late in evolution and is generally considered to facilitate static long-term gene silencing and to confer genome stability through repression of transposons and repetitive DNA elements (Yoder et al. 1997).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Yoder et al. 1997
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Recently, Hdac2 was genetically linked to the Wnt pathway, as Hdac2 is overexpressed in tumors and tissues from mice lacking the adenomatosis polyposis coli (APC) tumor suppressor (Zhu et al. 2004a).”
§ REVIEW Epigenetics and cancer > Histone acetylation
What the sources say
- Not checked yetcites Zhu et al. 2004a
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The PRMT5 arginine methyltransferase can methylate both histone H3 and H4 in vitro and interacts directly with components of the SWI/SNF complex (Pal et al. 2003).”
§ REVIEW Epigenetics and cancer > Arginine methyltransferases
What the sources say
- Not checked yetcites Pal et al. 2003
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Interestingly, mouse embryo fibroblasts deficient for Dnmt3b are resistant to transformation by SV40 largeT and activated Ras oncogenes (Soejima et al. 2003), demonstrating that epigenetic and genetic mechanisms likely act in concert during cellular transformation.”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Soejima et al. 2003
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“On the one hand, oncogenesis is promoted by local hypermethylation of tumor-suppressor genes, whereas global genomic hypomethylation, on the other hand, affects oncogene expression and genomic stability (Jones and Baylin 2002).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Jones and Baylin 2002
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Acetylation of histone proteins correlates with transcriptional activation and a dynamic equilibrium of histone acetylation is governed by the opposing actions of HATs and histone deacetylases (HDACs) (for recent reviews, see Marks et al. 2001;Yang 2004).”
§ REVIEW Epigenetics and cancer > Histone acetylation
What the sources say
- Not checked yetcites Marks et al. 2001
- Not checked yetcites Yang 2004
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“CpG dinucleotides are statistically underrepresented in the genome, likely because methylation of cytosine makes them more susceptible to deamination, but are locally enriched in shorter stretches of DNA (0.5 to several kilobases) known as CpG islands (Bird 2002).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Bird 2002
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Both genes reside in regions frequently lost in tumors, and cancerspecific mutations abolishing the enzymatic activity of p300 have been identified (Muraoka et al. 1996;Gayther et al. 2000;Ozdag et al. 2002).”
§ REVIEW Epigenetics and cancer > Histone acetylation
What the sources say
- Not checked yetcites Muraoka et al. 1996
- Not checked yetcites Gayther et al. 2000
- Not checked yetcites Ozdag et al. 2002
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“the regulatory regions of many genes (including known tumor suppressors) contain islands of repetitive sequences, some of which have been shown to influence transcriptional regulation (Jordan et al. 2003;Kelly 2003).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Jordan et al. 2003
- Not checked yetcites Kelly 2003
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Loss of imprinting of the IGF2 gene was recently suggested as a predictive marker for colorectal cancer (Cui et al. 2003).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Cui et al. 2003
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“CTCF is involved in the regulation of imprinting, where it is required to protect against de novo methylation (Fedoriw et al. 2004;Lewis and Murrell 2004).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Fedoriw et al. 2004
- Not checked yetcites Lewis and Murrell 2004
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Also, hypermethylation of tumor-suppressor genes may be an early event in cancer development (Waki et al. 2003;Lee et al. 2004;Suter et al. 2004), suggesting that epigenetic and mutational cancer causes may collaborate from an early time point in disease progression.”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Waki et al. 2003
- Not checked yetcites Lee et al. 2004
- Not checked yetcites Suter et al. 2004
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“it has been suggested that DNMTs may preferentially bind to damaged or mismatched DNA (James et al. 2003).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites James et al. 2003
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Epigenetic induction of a classical mutator phenotype via transcriptional inactivation of the DNA mismatch repair gene MLH1 has been proposed to account for microsatellite instability in colorectal cancers (Kane et al. 1997;Herman et al. 1998;Toyota et al. 1999a,b),”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Kane et al. 1997
- Not checked yetcites Herman et al. 1998
- Not checked yetcites Toyota et al. 1999a,b
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“In contrast to hypermethylation of tumor-suppressor genes, tumor cells globally display an overall hypomethylation of DNA (Feinberg and Vogelstein 1983a;Goelz et al. 1985) and hypomethylation was the first epigenetic mechanism to be linked to cancer development (Feinberg and Tycko 2004).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Feinberg and Vogelstein 1983a
- Not checked yetcites Goelz et al. 1985
- Not checked yetcites Feinberg and Tycko 2004
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Global genomic demethylation appears to progress with age in a tissue-dependent manner (Richardson 2003) and may in part explain the higher incidence of cancer among the elderly.”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Richardson 2003
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Genomic hypomethylation may furthermore cause genomic instability, presumably because demethylation predisposes to DNA strand breakage and recombination within derepressed repetitive sequences (for review, see Ehrlich 2002).”
§ REVIEW Epigenetics and cancer > DNA methylation
What the sources say
- Not checked yetcites Ehrlich 2002
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“BRG1/BRM expression was found lost in 10% of primary lung tumors correlating with a poor prognostic outcome (Reisman et al. 2003).”
§ REVIEW Epigenetics and cancer > Messing around with nucleosomes
What the sources say
- Not checked yetcites Reisman et al. 2003
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Noncoding antisense RNA driving DNA methylation”
§ REVIEW Epigenetics and cancer > Conclusions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The H2A variant H2AX marks DNA double-strand breaks, and H2AX-deficient cells have increased genomic instability and impaired forma-tion of radiation-induced foci of DNA repair proteins such as BRCA1 (Bassing et al. 2002;Celeste et al. 2002).”
§ REVIEW Epigenetics and cancer > Variant histones
What the sources say
- Not checked yetcites Bassing et al. 2002
- Not checked yetcites Celeste et al. 2002
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“DNA methylation driving histone modification”
§ REVIEW Epigenetics and cancer > Conclusions
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“In both mammals and flies, HP1 acts in a dosage-dependent manner with heterozygotes displaying a partial loss of gene silencing and HP1 overexpression resulting in an increase in silencing (Eissenberg et al. 1992;Festenstein et al. 1999).”
§ REVIEW Epigenetics and cancer > HP1 proteins
What the sources say
- Not checked yetcites Eissenberg et al. 1992
- Not checked yetcites Festenstein et al. 1999
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Histone modification directing DNA methylation”
§ REVIEW Epigenetics and cancer > Conclusions
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“HP1␣ and HP1 localize to pericentric heterochromatin and minor sites within euchromatin, whereas HP1␥ localizes predominantly to euchromatic regions (Eissenberg and Elgin 2000).”
§ REVIEW Epigenetics and cancer > HP1 proteins
What the sources say
- Not checked yetcites Eissenberg and Elgin 2000
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“These studies place Bmi1, and thereby epigenetic gene regulation, central to the emerging concept of tumor stem cells, which aside from having escaped cellular growth control mechanisms such as the p53 and the pRB pathways, also have (re)instigated a stem cell-like transcription program that allows for continuous self-renewal (Pardal et al. 2003;Valk-Lingbeek et al. 2004).”
§ REVIEW Epigenetics and cancer > Polycomb proteins
What the sources say
- Not checked yetcites Pardal et al. 2003
- Not checked yetcites Valk-Lingbeek et al. 2004
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“CENP-A was recently found to be overexpressed and mislocalized in primary human colorectal tumors, suggesting a link between CENP-A deregulation and aneuploidy (Tomonaga et al. 2003).”
§ REVIEW Epigenetics and cancer > Variant histones
What the sources say
- Not checked yetcites Tomonaga et al. 2003
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“the expression of HP1␣ is reportedly down-regulated in invasive human breast cancer cells, and overexpression of HP1␣ results in diminished invasive potential (Kirschmann et al. 2000).”
§ REVIEW Epigenetics and cancer > HP1 proteins
What the sources say
- Not checked yetcites Kirschmann et al. 2000
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Loss of Suv39h in mice results in the displacement of HP1 proteins from pericentromeric heterochromatin, resulting in anaploidy and cancer (Peters et al. 2001).”
§ REVIEW Epigenetics and cancer > HP1 proteins
What the sources say
- Not checked yetcites Peters et al. 2001
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
Epigenetic changes that contribute to cancer can be reversed pharmacologically to produce therapeutic benefit.
“In contrast to genetic cancer causes, the possibility of reversing epigenetic codes may provide new targets for therapeutic intervention.”
The paper relies on this without support.
Understanding the molecular details of epigenetic cancer mechanisms will translate into new drug development strategies.
“Understanding the molecular details behind”
The paper relies on this without support.
Findings from model organisms and cell lines are informative about human cancer epigenetics.
“Mouse models have further validated a role for genomic hypomethylation in tumor formation”
The paper relies on this without support.
Epigenetic alterations observed in cancer cell lines and xenografts reflect primary human tumor biology.
“MBD2 knockdown in human cancer cell lines was found to suppress tumorigenesis in a mouse xenograft model”
The authors state this as an assumption.
Reversal of epigenetic silencing will reinstate cellular cancer defense mechanisms.
“The fundamental principle behind this type of epigenetic therapy is that reversal of epigenetic silencing will reinstate cellular cancer defense mechanisms”
The paper relies on this without support.
There is limited knowledge about possible adverse effects in patients.
“relatively little is known about potential side effects in patients”
The paper relies on this without support.
Not all epigenetic marks are known.
“not all epigenetic marks are known”
The paper relies on this without support.
Only few of the known epigenetic marks are understood in any detail.
“only few of the known ones are understood in any detail”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both chromatin remodelling and DNA methylation have been linked to tumorigenesis119,120.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [119]
Citations
Cites
2 retracted
Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1
Beisel, C., Imhof, A., Greene, J., Kremmer, E., & Sauer, F. (2002) · Nature · doi:10.1038/nature01126 · Cited by 310
RetractedHairpin RNAs and Retrotransposon LTRs Effect RNAi and Chromatin-Based Gene Silencing
Schramke, V., & Allshire, R. C. (2003) · Science · doi:10.1126/science.1086870 · Cited by 307
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Flagged first, then by citations
3 of the 290 references couldn’t be matched to a known paper.
Research works printed but not linked: 26
- 2001, Cancer Res., 61, 2409
- 1999, Cancer Res., 59, 74
- 1999, Cancer Res., 59, 3855
- 2002, Cancer Res., 62, 4736
- 2001, Cancer Res., 61, 8094
- 2000, Cancer Res., 60, 2368
- 2001, Cancer Res., 61, 3225
- 2003, Clin. Cancer Res., 9, 4415
- 1995, Cancer Res., 55, 5195
- 1998, Cancer Res., 58, 4238
- 1995, Cancer Res., 55, 4525
- 1997, Cancer Res., 57, 808
- 2003, Cancer Res., 63, 7619
- 2000, Cancer Res., 60, 3359
- 1996, Oncogene, 12, 1565
- 1998, Cancer Res., 58, 591
- 2002, Curr. Issues Mol. Biol., 4, 111
- 1993, Oncogene, 8, 1063
- 2003, Int. J. Oncol., 23, 1663
- 2003, Cancer Res., 63, 1114
- 2003, Cancer Res., 63, 560
- 2003, Cancer Res., 63, 3511
- 1999, Cancer Res., 59, 5438
- 2002, Cancer Res., 62, 2378
- 1999, Nat. Genet., 23, 62
- 2000, Cancer Res., 60, 6171
Cited by
Sorted by citations
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,234
Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?
Baylin, S. B., & Ohm, J. E. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1799 · Cited by 1,657
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
RNAi-mediated pathways in the nucleus
Matzke, M. A., & Birchler, J. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1500 · Cited by 858
Vecsey, C. G., Hawk, J. D., Lattal, K. M., Stein, J. M., Fabian, S., Attner, M. A., Cabrera, S. M., McDonough, C. B., Brindle, P. K., Abel, T. G., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0296-07.2007 · Cited by 854
How is pluripotency determined and maintained?
Niwa, H. (2007) · Development · doi:10.1242/dev.02787 · Cited by 805
Chiba, T., Kita, K., Zheng, Y., Yokosuka, O., Saisho, H., Iwama, A., Nakauchi, H., & Taniguchi, H. (2006) · Hepatology · doi:10.1002/hep.21227 · Cited by 674
Doyon, Y., Cayrou, C., Ullah, M., Landry, A.-J., Côté, V., Selleck, W., Lane, W. S., Tan, S., Yang, X., & Côté, J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2005.12.007 · Cited by 656
MethSurv: A Web Tool to Perform Multivariable Survival Analysis Using DNA Methylation Data
Modhukur, V., Iljasenko, T., Metsalu, T., Lokk, K., Laisk, T., & Vilo, J. (2017) · Epigenomics · doi:10.2217/epi-2017-0118 · Cited by 645
Iron and cancer: recent insights
Manz, D. H., Blanchette, N. L., Paul, B. T., Torti, F. M., & Torti, S. V. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13008 · Cited by 507
Cancer chemoprevention by dietary polyphenols: Promising role for epigenetics
Link, A., Balaguer, F., & Goel, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.036 · Cited by 510
Epigenetic Transgenerational Actions of Endocrine Disruptors
Anway, M. D., & Skinner, M. K. (2006) · Endocrinology · doi:10.1210/en.2005-1058 · Cited by 455
Structure and E3‐ligase activity of the Ring–Ring complex of Polycomb proteins Bmi1 and Ring1b
Buchwald, G., van der Stoop, P. P. M., Weichenrieder, O., Anastassis Perrakis, A., van Lohuizen, M., & Sixma, T. K. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601144 · Cited by 453
The cancer epigenome—components and functional correlatesPreprint
Ting, A. H., McGarvey, K. M., & Baylin, S. B. (2006) · Genes & Development · doi:10.1101/gad.1464906 · Cited by 419
Laird, P. W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi113 · Cited by 409
Kaffman, A., & Meaney, M. J. (2007) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2007.01730.x · Cited by 391
Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors
Herceg, Z. (2007) · Mutagenesis · doi:10.1093/mutage/gel068 · Cited by 378
Theories of biological aging: Genes, proteins, and free radicals
Rattan, S. I. S. (2006) · Free Radical Research · doi:10.1080/10715760600911303 · Cited by 374
Nagarajan, R., Hogart, A., Gwye, Y., Martin, M. R., & LaSalle, J. M. (2006) · Epigenetics · doi:10.4161/epi.1.4.3514 · Cited by 347
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 309
Epigenetic transgenerational actions of endocrine disruptors
Skinner, M. K., Manikkam, M., & Guerrero‐Bosagna, C. (2010) · Reproductive Toxicology · doi:10.1016/j.reprotox.2010.10.012 · Cited by 313
Wei, Y., Xia, W., Zhang, Z., Liu, J., Wang, H., Adsay, V. N., Albarracin, C. T., Yu, D., Abbruzzese, J. L., Mills, G. B., et al. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20413 · Cited by 311
Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C. J., Williams-Truax, R., Mita, M. M., Beck, J., Burris, H. A., Ryan, G. F., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4262 · Cited by 296
Protein arginine-methyltransferase-dependent oncogenesis
Cheung, N., Chan, L.-C., Thompson, A., Cleary, M., & So, C. (2007) · Nature Cell Biology · doi:10.1038/ncb1642 · Cited by 298
Canonical and non-canonical JAK–STAT signaling
Li, W. X. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.008 · Cited by 300
Global Histone Modifications Predict Prognosis of Resected Non–Small-Cell Lung Cancer
Barlési, F., Giaccone, G., Gallegos-Ruiz, M. I., Loundou, A., Span, S. W., Lefesvre, P., Kruyt, F. A. E., & Rodríguez, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2599 · Cited by 280
Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids
Berquin, I. M., Min, Y.-N., Wu, R., Wu, J., Perry, D. L., Cline, J. M., Thomas, M. J., Thornburg, T., Kulik, G., Smith, A., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31494 · Cited by 280
Cancer Epigenetics: An Introduction
Kanwal, R., Gupta, K., & Gupta, S. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1804-1_1 · Cited by 266
Differential expression of selected histone modifier genes in human solid cancers
Özdağ, H., Teschendorff, A. E., Ahmed, A. A., Hyland, S. J., Blenkiron, C., Bobrow, L., Veerakumarasivam, A., Burtt, G. J., Subkhankulova, T., Arends, M. J., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-90 · Cited by 266
Lee, J. H., Khor, T. O., Shu, L., Su, Z., Fuentes, F., & Kong, A. T. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.008 · Cited by 254
Role of the Polycomb Repressive Complex 2 in Acute Promyelocytic Leukemia
Villa, R., Pasini, D., Gutiérrez, A., Morey, L., Occhionorelli, M., Viré, E. A., Nomdedeu, J. F., Jenuwein, T., Pelicci, P. G., Minucci, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.009 · Cited by 247
Recent advances of chroman-4-one derivatives: Synthetic approaches and bioactivities
Emami, S., & Ghanbarimasir, Z. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.02.048 · Cited by 229
Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma
Song, W., Li, H., Tao, K., Li, R., Song, Z. Q., Zhao, Q., Zhang, F., & Dou, K. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01777.x · Cited by 231
Li, J.-K., Chen, C. Y., Liu, J., Shi, J., Liu, S., Liu, B., Wu, D.-S., Fang, Z., Bao, Y., Jiang, M.-M., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0681-0 · Cited by 225
Belinostat: First Global Approval
Poole, R. M. (2014) · Drugs · doi:10.1007/s40265-014-0275-8 · Cited by 224
Methylation of Endogenous Human Retroelements in Health and Disease
Schulz, W. A., Steinhoff, C., & Florl, A. R. (2006) · Springer eBooks · doi:10.1007/3-540-31181-5_11 · Cited by 232
Luo, M., Brooks, M. D., & Wicha, M. S. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666141211120604 · Cited by 221
Histone deacetylase inhibitors in cancer therapy
Rasheed, W. K., Johnstone, R. W., & Prince, H. M. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.5.659 · Cited by 212
Concise Review: Roles of Polycomb Group Proteins in Development and Disease: A Stem Cell Perspective
Rajasekhar, V. K., & Begemann, M. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0608 · Cited by 210
Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing
Ferrés-Marcó, D., Gutierrez, I., Vallejo, D. M., Bolı́var, J., Gutiérrez-Aviñó, F. J., & Domínguez, M. (2006) · Nature · doi:10.1038/nature04376 · Cited by 205
Detection of Altered Global DNA Methylation in Coronary Artery Disease Patients
Sharma, P., Kumar, J., Garg, G., Kumar, A., Patowary, A., Karthikeyan, G., Ramakrishnan, L., Brahmachari, V., & Sengupta, S. (2008) · DNA and Cell Biology · doi:10.1089/dna.2007.0694 · Cited by 205
Kawazu, M., Saso, K., Tong, K. I., McQuire, T., Goto, K., Son, D.-O., Wakeham, A. C., Miyagishi, M., Mak, T. W., & Okada, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017830 · Cited by 201
DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment
Barton, C. A., Hacker, N. F., Clark, S. J., & O’Brien, P. M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.12.017 · Cited by 199
Jenke, R., Reßing, N., Hansen, F. K., Aigner, A. M., & Büch, T. (2021) · Cancers · doi:10.3390/cancers13040634 · Cited by 198
Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191
Hua, S., Kallen, C. B., Dhar, R., Baquero, M. T., Mason, C. E., Russell, B. A., Shah, P. K., Liu, J., Khramtsov, A., Tretiakova, M., et al. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.25 · Cited by 192
Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
Setiadi, A., Omilusik, K. D., David, M. D., Seipp, R. P., Hartikainen, J. A., Gopaul, R., Choi, K. B., & Jefferies, W. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5270 · Cited by 186
Kato, K., Long, N. K., Makita, H., Toida, M., Yamashita, T., Hatakeyama, D., Hara, A., Mori, H., & Shibata, T. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604521 · Cited by 184
Lo, P., & Sukumar, S. V. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.12.1879 · Cited by 191
Coolen, M. W., Stirzaker, C., Song, J. Z., Statham, A. L., Kassir, Z., Moreno, C. S., Young, A. N., Varma, V. A., Speed, T. P., Cowley, M. J., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2023 · Cited by 186
JAK signaling globally counteracts heterochromatic gene silencing
Shi, S., Calhoun, H. C., Fan, X., Li, J., Le, L. X., & Li, W. X. (2006) · Nature Genetics · doi:10.1038/ng1860 · Cited by 181
The Polycomb Group Protein EZH2 Is Required for Mammalian Circadian Clock Function
Etchegaray, J., Yang, X., DeBruyne, J. P., Peters, A. H. F. M., Weaver, D. R., Jenuwein, T., & Reppert, S. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603722200 · Cited by 177
Tumor suppressor p16 INK4A is necessary for survival of cervical carcinoma cell lines
McLaughlin-Drubin, M. E., Park, D., & Münger, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310432110 · Cited by 173
DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge
Castillo‐Aguilera, O., Depreux, P., Halby, L., Arimondo, P. B., & Goossens, L. (2017) · Biomolecules · doi:10.3390/biom7010003 · Cited by 166
Epigenetic aberrations and cancer.
Ducasse, M., & Brown, M. A. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-60 · Cited by 170
Using ChIP-Seq Technology to Generate High-Resolution Profiles of Histone Modifications
O’Geen, H., Echipare, L., & Farnham, P. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-316-5_20 · Cited by 174
Cancer chemoprevention: scientific promise, clinical uncertainty
Sporn, M. B., & Liby, K. T. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0319 · Cited by 157
Histone modifying enzymes and cancer: Going beyond histones
Zhang, K., & Dent, S. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20615 · Cited by 157
Pogribny, I. P., Ross, S. A., Tryndyak, V., Pogribna, M., Poirier, L. A., & Karpinets, T. V. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi364 · Cited by 155
Qiu, T., Zhou, L. Q., Zhu, W., Wang, T., Wang, J., Shu, Y., & Liu, P. (2013) · Future Oncology · doi:10.2217/fon.12.173 · Cited by 148
Xu, X., Tan, X., Tampe, B., Nyamsuren, G., Liu, X., Maier, L. S., Sossalla, S. T., Kalluri, R., Zeisberg, M., Hasenfuss, G. P., et al. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv015 · Cited by 145
Cui, X., Wakai, T., Shirai, Y., Hatakeyama, K., & Hirano, S. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj159 · Cited by 144
Gómez, C. E., Nájera, J. L., Krupa, M., & Estéban, M. (2008) · Current Gene Therapy · doi:10.2174/156652308784049363 · Cited by 139
Cellular memory and dynamic regulation of polycomb group proteins
Bantignies, F., & Cavalli, G. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.04.003 · Cited by 142
Su, Z., Shu, L., Khor, T. O., Lee, J. H., Fuentes, F., & Kong, A. T. (2012) · Topics in current chemistry · doi:10.1007/128_2012_340 · Cited by 139
Liu, S., Wang, J., Su, Y., Guerrero, C. R., Zeng, Y., Mitra, D., Brooks, P. J., Fisher, D. E., Song, H., & Wang, Y. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt360 · Cited by 140
The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation
Nicholson, T. B., Chen, T., & Richard, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.07.006 · Cited by 142
Giudice, F. S., Júnior, D. D. S. P., Nor, J. E., SQUARIZE, C. H., & CASTILHO, R. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058672 · Cited by 140
Cai, M.-Y., Hou, J.-H., Rao, H., Luo, R.-Z., Li, M., Pei, X., Lin, M. C. M., Guan, X., Kung, H., Zeng, Y.-X., et al. (2010) · Molecular Medicine · doi:10.2119/molmed.2010.00103 · Cited by 136
Tvardovskiy, A., Schwämmle, V., Kempf, S. J., Rogowska-Wrzesinska, A., & Jensen, O. N. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx696 · Cited by 132
Gopisetty, G., RAMACHANDRAN, K., & Singal, R. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.11.010 · Cited by 131
Korshunova, Y. O., Maloney, R. K., Lakey, N. D., Citek, R. W., Bacher, B., Budiman, A., Ordway, J. M., McCombie, W. R., Leon, J., Jeddeloh, J. A., et al. (2007) · Genome Research · doi:10.1101/gr.6883307 · Cited by 130
Liu, H., Dong, H., Robertson, K. D., & Liu, C. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.10.023 · Cited by 128
Connections between epigenetic gene silencing and human disease
Moss, T. J. M., & Wallrath, L. L. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2006.05.038 · Cited by 128
Bmi-1: At the crossroads of physiological and pathological biology
Bhattacharya, R., Mustafi, S. B., Street, M., Dey, A., & Dwivedi, S. K. D. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.04.001 · Cited by 132
Snigdha, S., Prieto, G. A., Petrosyan, A., Loertscher, B. M., Dieskau, A. P., Overman, L. E., & Cotman, C. W. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2693-15.2016 · Cited by 125
Tzao, C., Tung, H., Jin, J., Sun, G.-H., Hsu, H., Chen, B.-H., Yu, C., & Lee, S.-C. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.172 · Cited by 121
Lee, Y. J., Won, A. J., Lee, J., Jung, J. H., Yoon, S., Lee, B. M., & Kim, H. S. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.5011 · Cited by 123
Kanwal, R., & Gupta, S. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00066.2010 · Cited by 124
Methyl Deficiency, Alterations in Global Histone Modifications, and Carcinogenesis
Pogribny, I. P., Tryndyak, V., Muskhelishvili, L., Rusyn, I., & Ross, S. A. (2007) · Journal of Nutrition · doi:10.1093/jn/137.1.216s · Cited by 118
Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis
Clark, S. J. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm051 · Cited by 118
Ellis, L., Bots, M. L., Lindemann, R. K., Bolden, J. E., Newbold, A., Cluse, L. A., Scott, C. L., Strasser, A., Atadja, P. W., Lowe, S. W., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182758 · Cited by 117
Genome-wide tracking of unmethylated DNA Alu repeats in normal and cancer cells
Rodríguez, J., Vives, L., Jordà, M., Morales, C., Muñoz, M., Vendrell, E., & Peinado, M. A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm1105 · Cited by 119
Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors
Estiu, G. L., Greenberg, E. F., Harrison, C. B., Kwiatkowski, N. P., Mazitschek, R., Bradner, J. E., & Wiest, O. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7015254 · Cited by 111
MVA and NYVAC as Vaccines against Emergent Infectious Diseases and Cancer
Gómez, C. E., Nájera, J. L., Krupa, M., Perdiguero, B., & Estéban, M. (2011) · Current Gene Therapy · doi:10.2174/156652311795684731 · Cited by 108
Zhao, L., Li, W., Zang, W., Liu, Z., Xu, X., Yu, H., Yang, Q., & Jia, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0254 · Cited by 108
Keeping up NF-κB appearances: Epigenetic control of immunity or inflammation-triggered epigenetics
Berghe, W. V., Ndlovu, ’. N., Hoya-Arias, R., Dijsselbloem, N., Gerlo, S., & Haegeman, G. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.07.012 · Cited by 108
Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets
Ordway, J. M., Bedell, J. A., Citek, R. W., Nunberg, A. N., Garrido, A., Kendall, R., Stevens, J. R., Cao, D., Doerge, R. W., Korshunova, Y. O., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl161 · Cited by 108
Noncoding RNA in Oncogenesis: A New Era of Identifying Key Players
Deng, G., & Sui, G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918319 · Cited by 106
Magerl, C., Ellinger, J., Braunschweig, T. A., Kremmer, E., Koch, L.-K., Höller, T., Büttner, R., Lüscher, B., & Gütgemann, I. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.08.007 · Cited by 104
The role of Polycomb Group Proteins in Cell Cycle Regulation During Development
Martinez, A., & Cavalli, G. (2006) · Cell Cycle · doi:10.4161/cc.5.11.2781 · Cited by 111
Histone Modifications in Cancer Biology and Prognosis
Kurdistani, S. K. (2010) · Springer eBooks · doi:10.1007/978-3-7643-8989-5_5 · Cited by 106
Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury
Daosukho, C., Chen, Y., Noel, T. J., Sompol, P. M., Nithipongvanitch, R., Velez, J. M., Oberley, T. D., & Clair, D. K. S. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.03.007 · Cited by 102
Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma
Kavanaugh, S. M., White, L. A., & Kolesar, J. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090247 · Cited by 102
Song, J. S., Kim, Y. S., Kim, D. K., Park, S. I., & Jang, S. J. (2012) · Pathology International · doi:10.1111/j.1440-1827.2011.02776.x · Cited by 101
Fisher, C. L., Randazzo, F. M., Humphries, R. K., & Brock, H. W. (2006) · Gene · doi:10.1016/j.gene.2005.10.033 · Cited by 100
Frye, M., Fisher, A. G., & Watt, F. M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000763 · Cited by 100
Morales, C., Laugesen, A., & Helin, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060020 · Cited by 104
Sánchez‐Beato, M., Sánchez, E., González‐Carreró, J., Morente, M. M., Díez, A., Sánchez-Verde, L., Martín, M. C., Cigudosa, J. C., Vidal, M., & Piris, M. A. (2006) · Modern Pathology · doi:10.1038/modpathol.3800577 · Cited by 102
Metadata
- Authors
- Lund, A. H., & van Lohuizen, M.
- Affiliations
- The Netherlands Cancer Institute (NL)
- ORCID
- Lund, Anders H.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2004-10-01
- Volume
- 18
- Issue
- 19
- Pages
- 2315-2335
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2136492640
- Semantic Scholar
- a8eac694f349babbcdf21346ba0dfed461fa4e4f
- Cited by
- 489
- References
- 290
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 5 · 2023: 9 · 2022: 9 · 2021: 15 · 2020: 11 · 2019: 13 · 2018: 11 · 2017: 19 · 2016: 23 · 2015: 22 · 2014: 25 · 2013: 34 · 2012: 23
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- epigenetics, cancer, chromatin accessibility, DNA methylation, histone modifications, transcriptional regulation, tumor biology, cell cycle regulation, DNA repair, angiogenesis, cell migration, immune evasion, epigenetic therapy
- MeSH terms
- Cell Cycle, Cell Differentiation, Cell Division, DNA Repair, Gene Expression Regulation, Humans, Neoplasms, Neovascularization, Pathologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review